Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMar 25, 2026
DataAggregated Company Financials
Companies21
  • 7D-4.7%
  • 3M-26.6%
  • 1Y-47.6%
  • YTD-25.9%

Over the last 7 days, the Healthcare industry has dropped 4.7%, driven by Novo Nordisk declining 4.5%. However, the industry is down 48% over the past year. As for the next few years, earnings are expected to grow by 5.2% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Mar 2026DKK 1.4tDKK 447.6bDKK 130.0b16.3x11.1x3.2x
Fri, 20 Feb 2026DKK 1.8tDKK 447.5bDKK 131.0b18x13.8x4x
Sun, 18 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Tue, 16 Dec 2025DKK 1.9tDKK 453.7bDKK 136.9b16.9x13.9x4.2x
Thu, 13 Nov 2025DKK 1.9tDKK 453.4bDKK 136.0b18.2x14.2x4.3x
Sat, 11 Oct 2025DKK 2.2tDKK 447.6bDKK 141.8b18.2x15.4x4.9x
Mon, 08 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.5x4.6x
Wed, 06 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.5x14.5x4.3x
Fri, 04 Jul 2025DKK 2.4tDKK 423.0bDKK 124.4b30.5x19.2x5.6x
Sun, 01 Jun 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Tue, 29 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b22x19x5.6x
Thu, 27 Mar 2025DKK 2.7tDKK 409.6bDKK 121.3b23.5x22.3x6.6x
Sat, 22 Feb 2025DKK 3.3tDKK 410.0bDKK 121.4b28.1x27.6x8.2x
Mon, 20 Jan 2025DKK 3.1tDKK 387.5bDKK 111.3b28.5x27.9x8x
Wed, 18 Dec 2024DKK 3.9tDKK 387.4bDKK 111.3b30.1x35.5x10.2x
Fri, 15 Nov 2024DKK 3.9tDKK 387.1bDKK 110.8b31.9x35.3x10.1x
Sun, 13 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Tue, 10 Sep 2024DKK 4.5tDKK 372.0bDKK 107.2b35x42.5x12.2x
Thu, 08 Aug 2024DKK 4.3tDKK 355.3bDKK 106.3b36.2x40.2x12x
Sat, 06 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.3x46.2x13.8x
Mon, 03 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.8x44.1x13.2x
Wed, 01 May 2024DKK 4.6tDKK 341.4bDKK 99.6b33.7x46x13.4x
Fri, 29 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.2x45.4x13.3x
Sun, 25 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Tue, 23 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b35.2x41.8x11.7x
Thu, 21 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.6x40.1x11.3x
Sat, 18 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33.7x40x11.2x
Mon, 16 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b30.7x45x12.1x
Wed, 13 Sep 2023DKK 3.2tDKK 305.5bDKK 82.2b35.3x39x10.5x
Fri, 11 Aug 2023DKK 3.3tDKK 288.2bDKK 74.9b42.1x44.4x11.5x
Sun, 09 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Tue, 06 Jun 2023DKK 3.0tDKK 287.2bDKK 75.5b39.7x39.6x10.4x
Thu, 04 May 2023DKK 3.1tDKK 272.6bDKK 68.9b41.6x45.1x11.4x
Sat, 01 Apr 2023DKK 3.0tDKK 291.1bDKK 69.0b38.5x43.6x10.3x
Price to Earnings Ratio

43.6x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 69.0bTotal Revenue: DKK 291.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.1x which is lower than its 3-year average PE of 32.0x.
  • The 3-year average PS ratio of 9.1x is higher than the industry's current PS ratio of 3.2x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-4.18%
Healthcare-4.72%
Healthtech2.46%
Healthcare Services1.23%
Biotech-3.45%
Pharma-4.48%
Medical Equipment-5.80%
Life Sciences-26.21%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 483x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 11% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BAVA Bavarian NordicDKK 188.401.9%
+DKK 249.1m		18.2%PE10.6x
NNIT NNITDKK 43.502.7%
+DKK 28.6m		-41.3%PS0.6x
BIOPOR BioPortoDKK 0.912.3%
+DKK 9.9m		-36.5%PS12.3x
VIRO ViroGatesDKK 11.154.2%
+DKK 4.2m		37.7%PS12.8x
MONSO MonsensoDKK 0.1424.5%
+DKK 1.8m		-46.5%PS1x

Latest News

BAVA
DKK 188.40
Bavarian Nordic
7D
1.9%
1Y
18.2%
CHEMM
DKK 236.80
ChemoMetec
7D
-42.6%
1Y
-54.4%
ALK B
DKK 197.00
ALK-Abelló
7D
-7.5%
1Y
40.7%
NOVO B
DKK 238.00
Novo Nordisk
7D
-4.5%
1Y
-53.6%
AMBU B
DKK 67.60
Ambu
7D
-4.7%
1Y
-45.9%

AMBU B: Lower P/E Assumptions Will Support Upside If Execution Improves

Analysts have lowered their price target on Ambu by DKK 12 to reflect slightly adjusted assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E following the recent JPMorgan target cut to DKK 12. Analyst Commentary Bullish Takeaways Bullish analysts see the revised fair value and discount rate assumptions as a reset that could leave room for upside if Ambu delivers on its operational targets.
BIOPOR
DKK 0.91
BioPorto
7D
2.3%
1Y
-36.5%
NNIT
DKK 43.50
NNIT
7D
2.7%
1Y
-41.3%
GMAB
DKK 1,649.00
Genmab
7D
-3.7%
1Y
24.7%

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
COLO B
DKK 425.70
Coloplast
7D
-6.8%
1Y
-41.6%
DEMANT
DKK 179.20
Demant
7D
-3.8%
1Y
-29.3%

DEMANT: Recent Upgrade And 2026 Guidance May Support Further Upside

Our updated narrative keeps the fair value estimate steady at DKK 232.17 per share, reflecting a balanced view of recent Street research. One analyst raised Demant to a Buy with a DKK 230 target, while several others trimmed their price targets.
ZEAL
DKK 280.50
Zealand Pharma
7D
-5.7%
1Y
-50.4%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
MONSO
DKK 0.14
Monsenso
7D
24.5%
1Y
-46.5%
PEG
DKK 0.085
Pharma Equity Group
7D
0.5%
1Y
-40.8%
SMSMED
DKK 3.28
Scandinavian Medical Solutions
7D
1.2%
1Y
-19.2%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
VIRO
DKK 11.15
ViroGates
7D
4.2%
1Y
37.7%